



PB 25 of 2025

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 3)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 27 March 2025

REBECCA RICHARDSON
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division

Contents

1	Name.....	1
2	Commencement.....	1
3	Authority	1
4	Schedules.....	1
	Schedule 1—Amendments	2
	<i>National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).</i>	<i>2</i>

1 Name

- (1) This instrument is the *National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 3)*.
- (2) This instrument may also be cited as PB 25 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. <i>The whole of this instrument</i>	<i>1 April 2025</i>	<i>1 April 2025</i>

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

- [1] Schedule 1, after entry for Adalimumab in the form Injection 20 mg in 0.4 mL pre-filled syringe [Maximum quantity or number of units: 2; Maximum number of Repeats: 5]

insert:

		20	2	6
--	--	----	---	---

- [2] Schedule 1, entry for Clonazepam

omit:

Tablet 2 mg (S19A)		20	200	2
--------------------	--	----	-----	---

- [3] Schedule 1, entry for Estradiol

(a) *omit:*

Transdermal patches 585 micrograms, 24 (S19A)		20	1	1
---	--	----	---	---

(b) *omit:*

Transdermal patches 1.56 mg, 24 (S19A)		20	1	1
--	--	----	---	---

- [4] Schedule 1, after entry for Modafinil

insert:

Momelotinib	Tablet 100 mg (as dihydrochloride monohydrate)	20	30	0
		20	30	5
	Tablet 150 mg (as dihydrochloride monohydrate)	20	30	0
		20	30	5
	Tablet 200 mg (as dihydrochloride monohydrate)	20	30	0
		20	30	5

[5] Schedule 2, entry for Carmellose

(a) *omit:*

Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30	50	6	5
--	----	---	---

(b) *omit:*

Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30	50	6	5
---	----	---	---

[6] Schedule 2, entry for Medroxyprogesterone

omit:

Tablet containing medroxyprogesterone acetate 500 mg	50	60	2
--	----	----	---